2021
DOI: 10.1186/s13023-021-02120-9
|View full text |Cite
|
Sign up to set email alerts
|

Scientific evidence based rare disease research discovery with research funding data in knowledge graph

Abstract: Background Limited knowledge and unclear underlying biology of many rare diseases pose significant challenges to patients, clinicians, and scientists. To address these challenges, there is an urgent need to inspire and encourage scientists to propose and pursue innovative research studies that aim to uncover the genetic and molecular causes of more rare diseases and ultimately to identify effective therapeutic solutions. A clear understanding of current research efforts, knowledge/research gaps… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 20 publications
0
7
0
Order By: Relevance
“…Although SPOKE is limited to 137 diseases and lacks multimodal connections between textual clinical guidelines and tabular molecular data, it has enabled many precision medicine efforts, including overlaying individual patient information onto the SPOKE’s graph 35 . Another knowledge graph focused exclusively on rare diseases, Genetic and Rare Diseases Information Center (GARD) 34 , has advanced understanding of unmet medical needs and evidence-based studies for patients with under-diagnosed diseases 66 , 67 . Most recently, a White House initiative led the development of the COVID-19 Open Research Dataset (CORD-19) 68 .…”
Section: Background and Summarymentioning
confidence: 99%
“…Although SPOKE is limited to 137 diseases and lacks multimodal connections between textual clinical guidelines and tabular molecular data, it has enabled many precision medicine efforts, including overlaying individual patient information onto the SPOKE’s graph 35 . Another knowledge graph focused exclusively on rare diseases, Genetic and Rare Diseases Information Center (GARD) 34 , has advanced understanding of unmet medical needs and evidence-based studies for patients with under-diagnosed diseases 66 , 67 . Most recently, a White House initiative led the development of the COVID-19 Open Research Dataset (CORD-19) 68 .…”
Section: Background and Summarymentioning
confidence: 99%
“…Since authors and their affiliations are included in this KG, a collaborative network can be established among authors who are co-authors in the same articles or share similar research interests based on PubTator annotations. As a scientific evidence repository, it supports multi-KG integration with the NGKG (Zhu et al, 2020 ) ( https://disease.ncats.io/browser/ ) and the grant-based KG ( http://grants4rd.ncats.io:7474/browser/ ) (Zhu et al, 2021 ) based on their shared nodes including Disease nodes (i.e., GARD diseases) and Article nodes (i.e., PMIDs) for scientific evidence-based research study in RD.…”
Section: Discussionmentioning
confidence: 99%
“…(https://disease.ncats.io/ browser/) and the grant-based KG (http://grants4rd.ncats.io: 7474/browser/)(Zhu et al, 2021) based on their shared nodes including Disease nodes (i.e., GARD diseases) and Article nodes (i.e., PMIDs) for scientific evidence-based research study in RD.…”
mentioning
confidence: 99%
“…Clinical research is difficult in patients with rare diseases, and both pathophysiology and response to treatments can be poorly understood 9 . Muller et al have provided an excellent review of thoracic involvement in IgG4‐RD.…”
Section: Figurementioning
confidence: 99%
“…Clinical research is difficult in patients with rare diseases, and both pathophysiology and response to treatments can be poorly understood. 9 Muller et al have provided an excellent review of thoracic involvement in IgG4-RD. A review article such as this is an essential contribution to the literature and a valuable resource for clinicians and researchers.…”
mentioning
confidence: 99%